Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 13
1991 16
1992 13
1993 29
1994 22
1995 45
1996 43
1997 28
1998 23
1999 29
2000 36
2001 56
2002 50
2003 57
2004 59
2005 65
2006 42
2007 51
2008 48
2009 43
2010 35
2011 35
2012 40
2013 48
2014 32
2015 29
2016 36
2017 27
2018 15
2019 18
2020 11
2021 10
2022 8
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

1,045 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Pravastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Tasnim S, Wright JM. Adams SP, et al. Cochrane Database Syst Rev. 2023 Sep 18;9(9):CD013673. doi: 10.1002/14651858.CD013673.pub2. Cochrane Database Syst Rev. 2023. PMID: 37721222 Review.
BACKGROUND: A detailed summary and meta-analysis of the dose-related effect of pravastatin on lipids is not available. OBJECTIVES: Primary objective To assess the pharmacology of pravastatin by characterizing the dose-related effect and variability of the effect of …
BACKGROUND: A detailed summary and meta-analysis of the dose-related effect of pravastatin on lipids is not available. OBJECTIVES: Pr …
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Jones PH, et al. Am J Cardiol. 2003 Jul 15;92(2):152-60. doi: 10.1016/s0002-9149(03)00530-7. Am J Cardiol. 2003. PMID: 12860216 Clinical Trial.
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. ...After a dietary lea …
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastati …
Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.
Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, De Paco Matallana C, Cicero S, Greco E, Singh M, Janga D, Del Mar Gil M, Jani JC, Bartha JL, Maclagan K, Wright D, Nicolaides KH. Döbert M, et al. Circulation. 2021 Aug 31;144(9):670-679. doi: 10.1161/CIRCULATIONAHA.121.053963. Epub 2021 Jun 24. Circulation. 2021. PMID: 34162218 Clinical Trial.
Preeclampsia occurred in 14.6% (80 of 548) of participants in the pravastatin group and in 13.6% (74 of 543) in the placebo group. Allowing for the effect of risk at the time of screening and participating center, the mixed-effects Cox regression showed no evidence of an e …
Preeclampsia occurred in 14.6% (80 of 548) of participants in the pravastatin group and in 13.6% (74 of 543) in the placebo group. Al …
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Shepherd J, et al. Lancet. 2002 Nov 23;360(9346):1623-30. doi: 10.1016/s0140-6736(02)11600-x. Lancet. 2002. PMID: 12457784 Clinical Trial.
Mortality from coronary disease fell by 24% (p=0.043) in the pravastatin group. Pravastatin had no significant effect on cognitive function or disability. INTERPRETATION: Pravastatin given for 3 years reduced the risk of coronary disease in elderly individual …
Mortality from coronary disease fell by 24% (p=0.043) in the pravastatin group. Pravastatin had no significant effect on cogni …
Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study.
Akbar MIA, Yosediputra A, Pratama RE, Fadhilah NL, Sulistyowati S, Amani FZ, Dachlan EG, Dikman Angsar M, Dekker GA. Akbar MIA, et al. J Matern Fetal Neonatal Med. 2022 Dec;35(25):5375-5382. doi: 10.1080/14767058.2021.1879785. Epub 2021 Jan 31. J Matern Fetal Neonatal Med. 2022. PMID: 33522342 Clinical Trial.
Here we evaluate the effects of pravastatin on circulating inflammatory and endothelial markers, i.e. ...The direction of the effect of pravastatin on these biomarkers appears to underpin the potential for a beneficial effect of pravastatin in the prevention …
Here we evaluate the effects of pravastatin on circulating inflammatory and endothelial markers, i.e. ...The direction of the effect …
Statin therapy increases lipoprotein(a) levels.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Tsimikas S, et al. Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310. Eur Heart J. 2020. PMID: 31111151
-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day, rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. ...-statin pooled analysis, the ratio of geometric means (95% CI) for ato …
-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin …
Pravastatin in diabetes-associated hypercholesterolemia.
Rustemeijer C, Schouten JA, Janssens EN, Spooren PF, van Doormaal JJ. Rustemeijer C, et al. Acta Diabetol. 1997 Dec;34(4):294-300. doi: 10.1007/s005920050091. Acta Diabetol. 1997. PMID: 9451475 Clinical Trial.
Pravastatin treatment did not induce a significant change in high-density (HDL) cholesterol levels. ...No serious side effects occurred and pravastatin treatment did not cause any deterioration in glycemia control. ...
Pravastatin treatment did not induce a significant change in high-density (HDL) cholesterol levels. ...No serious side effects occurr …
A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.
Costantine MM, West H, Wisner KL, Caritis S, Clark S, Venkataramanan R, Stika CS, Rytting E, Wang X, Ahmed MS; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers (OPRC) Network, Bethesda, MD. Costantine MM, et al. Am J Obstet Gynecol. 2021 Dec;225(6):666.e1-666.e15. doi: 10.1016/j.ajog.2021.05.018. Epub 2021 May 24. Am J Obstet Gynecol. 2021. PMID: 34033812 Free PMC article. Clinical Trial.
Here, we report a follow-up, randomized trial of 20 mg pravastatin versus placebo among pregnant women with previous preeclampsia who required delivery before 34+6 weeks' gestation with the objective of evaluating the safety and pharmacokinetic parameters of pravastatin …
Here, we report a follow-up, randomized trial of 20 mg pravastatin versus placebo among pregnant women with previous preeclampsia who …
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Hennekens C. Hennekens C. Am J Cardiovasc Drugs. 2007;7 Spec No 1:9-11. doi: 10.1007/BF03262467. Am J Cardiovasc Drugs. 2007. PMID: 19839182 Review. French.
The rationale behind combined statin-acetylsalicylic acid therapy is based on the beneficial effects ofacetylsalicylic acid on thrombosis, the leading immediate cause of the majority of occlusive cardiovascular events, and those of statins on atherosclerosis, which is the main un …
The rationale behind combined statin-acetylsalicylic acid therapy is based on the beneficial effects ofacetylsalicylic acid on thrombosis, t …
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL, Lecomte T, Bouché O, Barbier E, Khemissa Akouz F, Riachi G, Nguyen Khac E, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM; PRODIGE-11 investigators/collaborators. Jouve JL, et al. J Hepatol. 2019 Sep;71(3):516-522. doi: 10.1016/j.jhep.2019.04.021. Epub 2019 May 22. J Hepatol. 2019. PMID: 31125576 Clinical Trial.
METHODS: The objective of the PRODIGE-11 trial was to compare the respective clinical outcomes of the sorafenib-pravastatin combination (arm A) versus sorafenib alone (arm B) in patients with advanced HCC. ...However, overall survival remains poor in these patients, so we …
METHODS: The objective of the PRODIGE-11 trial was to compare the respective clinical outcomes of the sorafenib-pravastatin combinati …
1,045 results

Searches related to "pravastatin"